ДЖИРАРДИ Майкл (GB),ГРИНХАЛФ Дэвид (GB),СПРЕЧЕР Дэннис Л. (US),УИЛЛЕТТ Роберт Николас (US)
申请号：
RU2014152454
公开号：
RU2014152454A
申请日:
2013.07.09
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of preventing or reducing the risk or severity of serious adverse cardiovascular events (MACE) in a subject who has previously suffered an episode of acute coronary syndrome (ACS), comprising administering the compound 6- (5-cyclopropylcarbamoyl-3-fluoro-2-methylphenyl) -N- (2,2-dimethylpropyl) -nicotinamide or a pharmaceutically acceptable soli.2. A method according to Claim. 1, wherein said MACE is unstable angina (UA) .3. A method according to Claim. 1, wherein said MACE is myocardial infarction with ST-segment elevation (STEMI) .4. A method according to Claim. 1, wherein said MACE is a myocardial infarction without ST-segment lift (NSTEMI) .5. A method of reducing vascular inflammation and / or stabilization of atherosclerotic plaque in a subject who has previously suffered an episode of acute coronary syndrome (ACS), comprising administering the compound 6- (5-cyclopropylcarbamoyl-3-fluoro-2-methylphenyl) -N- (2,2- dimethylpropyl) -nicotinamide or a pharmaceutically acceptable soli.6. A method for protecting the myocardium and to improve its function during and after the episode of acute coronary syndrome (ACS), comprising administering the compound 6- (5-cyclopropylcarbamoyl-3-fluoro-2-methylphenyl) -N- (2,2-dimethylpropyl) -nicotinamide or its pharmaceutically acceptable soli.7. A method according to any one of claims. 1, 5 or 6, wherein the compound is in the form of free osnovaniya.8. A method according to any one of claims. 1, 5 or 6, wherein the compound is administered vnutrivenno.9. A method according to any one of claims. 1, 5 or 6, wherein the compound is administered peroralno.10. A method according to claim. 9, wherein the compound is administered within 3 months after this episode of acute coronary syndrome (ACS) .11. A method according to any one of claims. 1, 5 or 6, wherein the compound is administered in combination with an additional therapeutic agentom.12. The method of claim. 11 wherein the compound is administered in combination
